(H.E.L.P.)Apheresis Therapy to Compare the Reduction of LDL (Low Density Lipoprotein) Cholesterol

Inclusion Criteria: * Subject is between 25 and 70 years of age (inclusive) at the time of randomization. * Subject is an appropriate candidate for H.E.L.P. apheresis treatment for hypercholesterolemia according to current Plasmat® Secura approval criteria. * Subject has received a minimum of two consecutive bi-monthly\* H.E.L.P. apheresis treatments using the Plasmat® Secura apheresis system \>30 days prior to the screening visit. * Subject is willing to maintain cholesterol lowering dietary and drug therapies as prescribed through the course of the study. * Subject is willing and able to provide written informed consent and Health Insurance Portability and Accountability Act (HIPAA) Waiver. * Sterile, post-menopausal, or using acceptable birth control for the duration of the study. Acceptable birth control is defined as having a vasectomized, postmenopausal, or sterile partner; the ongoing use of approved hormonal contraceptives, barrier method, or an intrauterine device; or abstinence. * Every 14 days (±2 days) Exclusion Criteria: * A History of a known sensitivity to heparin or ethylene oxide. * A history of hemorrhagic diathesis, bleeding/clotting disorder, thrombocytopenia (defined as platelet count \< 150 x109/L), or for whom the use of heparin would cause excessive or uncontrolled anticoagulation or for whom adequate anticoagulation cannot be safely achieved (ie., hemophilia, recent surgery, acute internal bleeding, gastrointestinal ulcers). * Females who are pregnant or lactating. * Subjects\< 106 lbs. or \<48.2 kg in body weight; or whose weight is \>1.5 times their ideal weight. * Certain cardiac impairments such as congestive heart failure, major arrhythmia, or diastolic blood pressure greater than 100 mm/Hg on two separate occasions at least 24 hours apart. * Renal insufficiency defined as creatinine greater \>2.0 mg/dlL or is dependent upon renal dialysis. * Untreated hypothyroidism; uncontrolled diabetes mellitus; or fasting triglycerides \>500 mg/dL. * Serious systemic disease (e.g., advanced neoplasms, and acute hepatitis) including Immune system suppression or compromise, that could preclude survival to study completion. * History of stroke within 6 months of the screening visit. * Received thrombolytic treatment \< 7 days of screening.visit. * Taken or requires a prohibited treatment \< 30 days prior to the Screening Visit, or requires a prohibited treatment at anytime during the course of the study. * Neutropenia (neutrophil count \< 0.5 x109/L). * History of liver disease or serum ALT and/or AST \> 2X upper limit of normal range. * History of dementia. * History of anemia (value outside the lower normal range). * acetyl salicylic acid (ASA) \> 325 mg/day. * Subject currently enrolled in another investigational study (does not apply to PMS for Secura device). * Subject with any other medical condition that in the opinion of the investigator might put the subject at risk or interfere with his/her participation. * Subject is unwilling or unable to comply with the protocol or to cooperate fully with the investigator or site personnel.